Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (AC

GUIDELINE TITLE
Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). (Addendum 1) Recommendations for all persons aged 11--18 years; (Addendum 2) Recommendations for children aged 2--10 years at increased risk for invasive meningococcal disease.

BIBLIOGRAPHIC SOURCE(S)
Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005 May 27;54(RR-7):1-21. [146 references] PubMed

Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices. Revised recommendations of the Advisory Committee on Immunization Practices to Vaccinate all Persons Aged 11-18 Years with Meningococcal Conjugate Vaccine. MMWR Morb Mortal Wkly Rep 2007 Aug 10;56(31):794-5. [6 references] PubMed

Recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2-10 years at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2007 Dec 7;56(48):1265-6. [6 references]

GUIDELINE STATUS
This is the current release of the guideline.

This addendum updates a previous version: Centers for Disease Control and Prevention. Notice to readers: improved supply of meningococcal conjugate vaccine, recommendation to resume vaccination of children 11--12 years. MMWR Recomm Rep 2006 Nov 3;55(43):1177. [2 references]

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

April 14, 2009 - Rocephin (ceftriaxone sodium): The U.S. Food and Drug Administration (FDA) notified healthcare professionals of an update to a previous alert that addresses the interaction of ceftriaxone with calcium-containing products, based on previously reported fatal cases in neonates. Based on the results from recent in vitro studies, FDA now recommends that ceftriaxone and calcium-containing products may be used concomitantly in patients >28 days of age, using the precautionary recommendations noted because the risk of precipitation is low in this population. FDA had previously recommended, but no longer recommends, that in all age groups ceftriaxone and calcium-containing products should not be administered within 48 hours of one another.
July 08, 2008 - Fluoroquinolones (ciprofloxacin, norfloxacin, ofloxacin, levofloxacin, moxifloxacin, gemifloxacin): A BOXED WARNING and Medication Guide are to be added to the prescribing information to strengthen existing warnings about the increased risk of developing tendinitis and tendon rupture in patients taking fluoroquinolones for systemic use.

abrir aquí para acceder al documento NGC AHRQ completo:
Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (AC